HC Wainwright Estimates Aethlon Medical Q2 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Research analysts at HC Wainwright issued their Q2 2027 EPS estimates for shares of Aethlon Medical in a report released on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth expects that the medical equipment provider will post earnings per share of ($3.64) for the quarter. HC Wainwright currently has a “Neutral” rating and a $1.50 price target on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($16.15) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.14) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.22) EPS.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10).

AEMD has been the subject of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. Wall Street Zen raised Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and an average price target of $1.50.

Aethlon Medical Stock Performance

AEMD opened at $2.78 on Thursday. The business’s 50-day simple moving average is $4.40 and its 200-day simple moving average is $8.51. Aethlon Medical has a one year low of $2.63 and a one year high of $137.00. The stock has a market capitalization of $1.97 million, a P/E ratio of -0.08 and a beta of 1.41.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.